Mayne Pharma Group Ltd (ASX:MYX)
Share Price & News Healthcare

AUD 4.13 -0.02 (0.482%)

(As on 2023-05-04 08:56:32 AEDT)
Previous Close Open Close* Market Capitalization Dividend Yield Day Range 52 WEEK HIGH LOW
$4.15 $4.15 $4.13 $351.36 M -- $3.98 L $4.15 H $2.68 L $8.50 H

Chart Price & Info

Note: Kalkine Pty Limited (“Kalkine”) may display, include or make available third-party content including charts or any other data (“Third Party Content”) on its website/app. You acknowledge and agree that Kalkine is not responsible for Third Party Content including their accuracy, content, reliability or any other aspect thereof. Kalkine will not accept liability for any loss or damage, including without limitation any loss of profit, which may arise directly or indirectly from use of or reliance on such Third Party Content. All Third Party Content is the exclusive property of their respective owners.

Last Trade 4.13
Change% -0.4819
52 W H/L
EBITDA -208.49 M$
Net Profit
After Abnormals
$-263.34 M
Capital $557.12 M
Return on Equity (ROE) -9.48%
Total Liabilities 730.81 M
Total Revenue 429.53 M
Cash 96.67 M

Stock Information*

Share price 4.13
Market Capitalization 351356809
Price to Gross Cash Flow 4.51
Dividend Yield Excluding Special 0.00%
Diluted Share outstanding 88.24 M
Gross Dividend Per Share $0.038900000000000004
Dividend Yield 15.54%
Earnings Yield
Net Tangible Assets Per Share 0.08
PE Ratio --
Sector P/E --
Earnings per Share (EPS) (cents) -16.00
EV to EBITDA 7.22
Net Profit Margin -12.63%
Gross Cash Flow Per Share $1.19
Net Gearing 56.90%
Sales Per Share $5.15
Book Value Per Share $0.32

Similar Companies

About Company

Mayne Pharma Group Limited is a specialty pharmaceutical company. The Company is focused on applying its drug delivery to commercialize branded and generic pharmaceuticals. The Company's operating segments are Mayne Pharma International (MPI), US Products (USP) and Metrics Contract Services (MCS). The MPI segment is engaged in manufacture and sale of branded and generic pharmaceutical product and provision of contract manufacturing services to third-party customers within Australia. The USP segment is engaged in the manufacture and distribution of generic and branded pharmaceutical products in the United States. The MCS segment provides contract pharmaceutical development services to third-party customers in the United States. The Company's products include Astrix, Doryx, Eryc, Kadian, Kapanol, Magnoplasm, Lozanoc, SUBA-Itraconazole, ZEBUTAL, ESGIC, ESGIC PLUS, LORCET and LORCET PLUS. The Company also provides contract development and manufacturing services to its clients.

Corporate Information

company address 1538 Main North Rd, Salisbury South, SA, 5106

company phonePhone:   +61 3 8209 2666

company emailEmail:  [email protected]

company website Website:

Event Calendar*

Event Type Event Date Event Year
Report (Interim) 2024-02-27 2024 upcoming
Report (Annual) 2023-10-12 2023
Report (Prelim) 2023-08-25 2023


© Data powered by Morningstar, Inc. 2023. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.